Collectively, these findings establish a BA-bromodomain axis as a transcriptional interface linking metabolic signaling and chromatin regulation, and highlight FXR-BET targeting as a promising strategy to counter progressive β cell failure in diabetes. The gene discussed is NR1H4; the disease is diabetes mellitus.